ACADIA Pharmaceuticals Inc

ACAD

NASDAQ. Currency in USD

15.10 -0.29 ( -1.88% )

Real time prices: December 19

Market Cap.
2.45B
Beta (5Y monthly)
0.60
Price/Earnings
-
EPS (TTM)
-1.35
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.05M
1y Target Est.
18.50
Day's Range
14.88
-
15.47
52 Week's Range
12.24
-
28.05

Historical Summary

Performance
EPS growth
Share Buybacks

About ACADIA Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.acadia-pharm.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
160.76M
Employees
510
Address
12830 El Camino Real, San Diego, CA, United States, 92130
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Latest news

Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 8 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to...
By Benzinga - 12 weeks ago

Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall...
By Zacks Investment Research - 12 weeks ago

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter...
By Zacks Investment Research - 12 weeks ago

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An...
By Zacks Investment Research - 12 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio...
By Benzinga - 12 weeks ago

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and...
By Zacks Investment Research - 13 weeks ago

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely...
By Zacks Investment Research - 13 weeks ago